Metabolic Reprogramming Offers New Path to Halt Progressive Multiple Sclerosis
A major review reveals how immune cell metabolism drives MS progression — and how targeting it could finally repair myelin.
Summary
Multiple sclerosis has long been treated as a pure autoimmune disease, but modern immunotherapies fail to stop progressive neurodegeneration. This review reframes MS as also a metabolic disorder: proinflammatory immune cells rely on aerobic glycolysis driven by mTOR and HIF-1α, while protective cells and neurons depend on fatty acid oxidation via AMPK. When glycolysis dominates, chronic inflammation persists and myelin repair fails. Excitingly, existing MS drugs like dimethyl fumarate and teriflunomide appear to work partly through metabolic mechanisms. Emerging therapies — including metformin (AMPK activation), glutaminase inhibitors, mTOR inhibitors, and NAD+ precursors — specifically target this metabolic imbalance to promote remyelination and reduce neuroinflammation. The authors argue this metabolic lens opens a new therapeutic era for progressive MS.
Detailed Summary
Multiple sclerosis afflicts millions worldwide, and while current immunotherapies can reduce relapses, they largely fail patients with progressive disease — leaving neurodegeneration and remyelination failure unaddressed. This review proposes a transformative reframing: metabolic dysregulation is not merely a bystander in MS but an active driver of disease that can be therapeutically corrected.
The paper synthesizes evidence showing that bioenergetic programming determines whether immune and neural cells behave protectively or pathologically. Proinflammatory Th17 cells and M1 microglia — the key damage-inflicting actors in MS — depend on aerobic glycolysis and glutaminolysis, processes regulated by mTOR and HIF-1α signaling. Conversely, regulatory T cells, anti-inflammatory M2 microglia, and neurons rely on fatty acid oxidation and oxidative phosphorylation governed by AMPK. In MS, the balance shifts catastrophically toward glycolysis, fueling chronic neuroinflammation and blocking repair.
A striking finding is that established MS therapies already exploit these metabolic vulnerabilities without that being their recognized mechanism. Dimethyl fumarate modulates the Nrf2 pathway and disrupts glycolytic flux; teriflunomide inhibits mitochondrial dihydroorotate dehydrogenase. This retroactive validation strengthens the case for intentional metabolic targeting.
Emerging strategies reviewed include glutaminase inhibitors to suppress pathogenic Th17 activity, metformin as an AMPK activator to enhance oligodendrocyte remyelination, mTOR inhibitors to restore immune regulatory balance, and NAD+ precursors to rejuvenate mitochondrial function in aging and inflamed neural tissue. Each approach targets a distinct metabolic node with potential synergistic benefit.
The clinical translation of these strategies, however, requires carefully designed trials and validated metabolic biomarkers. The review calls for a shift from broad immunosuppression toward precision metabolic pharmacology — a paradigm with meaningful implications not just for MS but for age-related neuroinflammatory conditions broadly.
Key Findings
- Proinflammatory MS immune cells run on aerobic glycolysis; shifting them to oxidative metabolism may halt neuroinflammation.
- Existing MS drugs dimethyl fumarate and teriflunomide work partly via previously unrecognized metabolic mechanisms.
- Metformin (AMPK activator) shows promise for enhancing remyelination in progressive MS.
- NAD+ precursors may rejuvenate mitochondrial function in neurons damaged by chronic neuroinflammation.
- mTOR inhibitors and glutaminase inhibitors represent emerging tools to restore immune-metabolic balance in MS.
Methodology
This is a narrative review synthesizing published evidence on immunometabolism in MS pathogenesis and therapeutic targeting. It draws on mechanistic studies, preclinical models, and clinical data for existing and emerging MS therapies. No original experimental data were generated.
Study Limitations
This summary is based on the abstract only, as the full text is behind a paywall. As a narrative review, the paper is subject to selection bias in cited literature and does not include a formal meta-analytic synthesis. Clinical validation of the proposed metabolic therapies via rigorous trials remains pending, and reliable biomarkers for patient stratification have not yet been established.
Enjoyed this summary?
Get the latest longevity research delivered to your inbox every week.
Enter your email to subscribe: